About Moderna
Industry:
Biotechnology
Founded:
2010
Founders:
Noubar Afeyan, Robert Langer, Derrick Rossi, Kenneth Chien
Status:
Public (NASDAQ: MRNA)
Funding & Growth
Total Raised:
$6B+
Valuation:
$40B+ market cap
Stage:
Public
Key Investors:
Flagship Pioneering
AstraZeneca
Merck
✓ Pros
- • Revolutionary mRNA technology
- • Exceptional compensation and equity
- • Fast-paced innovation culture
- • Strong pipeline beyond COVID
- • Boston/Cambridge location
✗ Cons
- • Very demanding work environment
- • High pressure and fast pace
- • Work-life balance challenges
- • Post-COVID uncertainty